Mark Ozeck

1.2k total citations
22 papers, 878 citations indexed

About

Mark Ozeck is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark Ozeck has authored 22 papers receiving a total of 878 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 9 papers in Oncology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark Ozeck's work include Adenosine and Purinergic Signaling (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Neuroendocrine Tumor Research Advances (3 papers). Mark Ozeck is often cited by papers focused on Adenosine and Purinergic Signaling (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Neuroendocrine Tumor Research Advances (3 papers). Mark Ozeck collaborates with scholars based in United States, South Korea and China. Mark Ozeck's co-authors include John C. Shryock, Luiz Belardinelli, James G. Christensen, L Belardinelli, Maruja E. Lira, Xianxian Zheng, Paul A. Rejto, Keith A. Ching, Guy Servant and Paul F. Brust and has published in prestigious journals such as Circulation Research, Cancer Research and Clinical Cancer Research.

In The Last Decade

Mark Ozeck

21 papers receiving 863 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Ozeck United States 14 457 263 191 177 167 22 878
Dagmar Schumacher Germany 11 234 0.5× 305 1.2× 80 0.4× 90 0.5× 114 0.7× 14 765
Valentina Poletto Italy 20 381 0.8× 83 0.3× 107 0.6× 97 0.5× 60 0.4× 35 916
Céline Delierneux Belgium 13 270 0.6× 110 0.4× 111 0.6× 55 0.3× 76 0.5× 23 599
Nancy J. Boerth United States 17 787 1.7× 134 0.5× 41 0.2× 101 0.6× 129 0.8× 17 1.7k
Yung‐Wu Chen United States 12 522 1.1× 60 0.2× 34 0.2× 52 0.3× 322 1.9× 24 963
Hongliang Luo China 16 316 0.7× 132 0.5× 99 0.5× 140 0.8× 239 1.4× 63 735
S. Kelly Ambler United States 12 516 1.1× 134 0.5× 24 0.1× 71 0.4× 91 0.5× 17 955
Silvia Vega-Rubín-de-Celis Germany 12 611 1.3× 77 0.3× 143 0.7× 75 0.4× 164 1.0× 20 1.0k
Christian Kamp Nielsen Sweden 11 386 0.8× 165 0.6× 49 0.3× 41 0.2× 74 0.4× 12 687

Countries citing papers authored by Mark Ozeck

Since Specialization
Citations

This map shows the geographic impact of Mark Ozeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Ozeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Ozeck more than expected).

Fields of papers citing papers by Mark Ozeck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Ozeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Ozeck. The network helps show where Mark Ozeck may publish in the future.

Co-authorship network of co-authors of Mark Ozeck

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Ozeck. A scholar is included among the top collaborators of Mark Ozeck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Ozeck. Mark Ozeck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yan, Wen, Chi‐Yeh Chung, Tao Xie, et al.. (2021). Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4‐driven transcriptional state. Molecular Oncology. 16(6). 1309–1328. 19 indexed citations
2.
Clark, Jeffrey W., D. Ross Camidge, Eunice L. Kwak, et al.. (2019). Dose-Escalation Trial of the ALK, MET & ROS1 Inhibitor, Crizotinib, in Patients with Advanced Cancer. Future Oncology. 16(1). 4289–4301. 12 indexed citations
3.
Ching, Keith A., Donghui Huang, Kai Wang, et al.. (2018). Abstract LB-215: Analysis of mutations associated with response to glasdegib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Cancer Research. 78(13_Supplement). LB–215. 3 indexed citations
4.
Wang, Kai, Qin Zhang, Danan Li, et al.. (2015). PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor. Clinical Cancer Research. 21(6). 1487–1496. 122 indexed citations
5.
Lira, Maruja E., Yoon‐La Choi, Sun Min Lim, et al.. (2014). A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer. Journal of Molecular Diagnostics. 16(2). 229–243. 88 indexed citations
6.
Fang, Douglas D., Bin Zhang, Qingyang Gu, et al.. (2014). HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib. Journal of Thoracic Oncology. 9(3). 285–294. 74 indexed citations
7.
Jackson-Fisher, Amy, Pamela Whalen, Mark Elliott, et al.. (2014). Abstract 1958: Interrogating hedgehog pathway and smoothened inhibition by PF-04449913 in patient-derived acute myeloid leukemia models. Cancer Research. 74(19_Supplement). 1958–1958. 5 indexed citations
8.
Pavlı́c̀ek, Adam, Maruja E. Lira, Nathan V. Lee, et al.. (2013). Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871). Molecular Cancer Therapeutics. 12(12). 2929–2939. 31 indexed citations
9.
Lira, Maruja E., Yoon‐La Choi, Shibing Deng, et al.. (2013). Abstract 3493: A single-tube, multiplexed, transcript-based assay to detect ALK, ROS1 and RET fusions in lung cancer.. Cancer Research. 73(8_Supplement). 3493–3493.
10.
Hook, Kenneth E., Maruja E. Lira, Keith A. Ching, et al.. (2012). An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735. Molecular Cancer Therapeutics. 11(3). 710–719. 77 indexed citations
11.
Zhang, Cathy C., Adam Pavlı́c̀ek, Qin Zhang, et al.. (2012). Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models. Clinical Cancer Research. 18(18). 5008–5019. 53 indexed citations
12.
Zou, Helen Y., Qiuhua Li, Joseph Lee, et al.. (2008). Receptor tyrosine kinase cross talk affects tumor cell sensitivity to RTK inhibitors. Cancer Research. 68. 2 indexed citations
13.
Ozeck, Mark, Paul F. Brust, Hong Xu, & Guy Servant. (2004). Receptors for bitter, sweet and umami taste couple to inhibitory G protein signaling pathways. European Journal of Pharmacology. 489(3). 139–149. 60 indexed citations
14.
Fraser, Heather, Zhenhai Gao, Mark Ozeck, & Luiz Belardinelli. (2003). N-[3-(R)-Tetrahydrofuranyl]-6-aminopurine Riboside, an A1 Adenosine Receptor Agonist, Antagonizes Catecholamine-Induced Lipolysis without Cardiovascular Effects in Awake Rats. Journal of Pharmacology and Experimental Therapeutics. 305(1). 225–231. 15 indexed citations
15.
16.
Belardinelli, Luiz, et al.. (2002). Tonic activity of the rat adipocyte A1‐adenosine receptor. British Journal of Pharmacology. 135(6). 1457–1466. 32 indexed citations
17.
Grant, Maria B., Roy Tarnuzzer, Sergio Caballero, et al.. (1999). Adenosine Receptor Activation Induces Vascular Endothelial Growth Factor in Human Retinal Endothelial Cells. Circulation Research. 85(8). 699–706. 139 indexed citations
18.
Shryock, John C., Mark Ozeck, & L Belardinelli. (1998). Inverse Agonists and Neutral Antagonists of Recombinant Human A1 Adenosine Receptors Stably Expressed in Chinese Hamster Ovary Cells. Molecular Pharmacology. 53(5). 886–893. 72 indexed citations
19.
Kollias-Baker, Cynthia, Marlene A. Jacobson, Jeffrey K. Harrison, et al.. (1997). Agonist-Independent Effect of an Allosteric Enhancer of the A1 Adenosine Receptor in CHO Cells Stably Expressing the Recombinant Human A1 Receptor. Journal of Pharmacology and Experimental Therapeutics. 281(2). 761–768. 41 indexed citations
20.
Gralinski, Michael, Simon Black, Louis F. Stancato, et al.. (1996). Heat stress protects the perfused rabbit heart from complement-mediated injury. American Journal of Physiology-Heart and Circulatory Physiology. 271(2). H571–H578. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dagmar Schumacher Breakdown of academic impact, for papers by Valentina Poletto Breakdown of academic impact, for papers by Céline Delierneux Breakdown of academic impact, for papers by Nancy J. Boerth Breakdown of academic impact, for papers by Yung‐Wu Chen Breakdown of academic impact, for papers by Hongliang Luo Breakdown of academic impact, for papers by S. Kelly Ambler Breakdown of academic impact, for papers by Silvia Vega-Rubín-de-Celis Breakdown of academic impact, for papers by Christian Kamp Nielsen
Rankless by CCL
2026